Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;26(1):77-84.
doi: 10.1007/s12264-010-0703-z.

Roles of the prostaglandin E2 receptors EP subtypes in Alzheimer's disease

Li-Li Wei  1 , Yue-Di Shen, Ying-Chun Zhang, Xing-Yue Hu, Pei-Ling Lu, Li Wang, Wei Chen
Affiliations
Review

Roles of the prostaglandin E2 receptors EP subtypes in Alzheimer's disease

Li-Li Wei et al. Neurosci Bull. 2010 Feb.

Abstract
in English, Chinese

Neuroinflammation has always been of concern in the pathogenesis of Alzheimer's disease (AD). As a major inflammatory mediator, prostaglandin E(2) (PGE(2)) plays an important role in the inflammatory process of AD. Up to now, there is still controversy on the neuroprotective or neurotoxic role of PGE(2). However, the role of PGE(2) in neurodegeneration may be far more complex, due to the 4 EP receptor subtypes. This article aims to summarize the relationship between PGE(2) receptor EP subtypes and AD. It is believed that a better understanding of the PGE(2) receptor EP subtypes may help to clarify the relation between inflammation and AD, and to develop novel therapeutic strategies targeting specific EP receptor for AD treatment.

神经炎症在阿尔茨海默病(Alzheimer’s disease, AD)发病机制中的作用一直备受关注。 前列腺素E2(PGE2)作为 一个主要的炎症介质, 在AD的炎症过程中发挥着重要的作用 。 然而, 目前关于PGE2 对神经元是保护还是损害仍 存有分歧。 PGE2 受体存在EP1-4 四类亚型, 因此要探讨PGE2在神经元损伤中扮演的角色, 我们需综合考虑下游信 号通路的作用。 本文旨在综述PGE2受体EP亚型与AD的关系。 对PGE2受体EP亚型的进一步研究将有助于阐明炎 症与AD 的联系, 为AD 治疗找到新的靶点。

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wan Y., Wang G., Chen S.D. Genetic predisposition to inflammation: a new risk factor of Alzheimer’s disease. Neurosci Bull. 2008;24:314–322. doi: 10.1007/s12264-008-0619-z. - DOI - PMC - PubMed
    1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21:383–421. doi: 10.1016/S0197-4580(00)00124-X. - DOI - PMC - PubMed
    1. Etminan M., Gill S., Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:128. doi: 10.1136/bmj.327.7407.128. - DOI - PMC - PubMed
    1. in t’ Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med. 2001;345:1515–1521. doi: 10.1056/NEJMoa010178. - DOI - PubMed
    1. Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review. Neuroepidemiology. 2004;23:159–169. doi: 10.1159/000078501. - DOI - PubMed

Publication types